Literature DB >> 27009921

Paediatric non-Hodgkin lymphoma - perspectives in translational biology.

Bruce Shiramizu1, Lara Mussolin2,3, Wilhelm Woessmann4,5, Wolfram Klapper6.   

Abstract

Exciting advances have been achieved for infants, children and adolescents diagnosed with, and treated for, non-Hodgkin lymphoma (NHL). In spite of these successes, new frontiers are being paved to improve the prognosis for those who relapse or have resistant disease. This review summarizes some of the novel approaches and ideas in NHL monitoring, diagnosis and treatment as discussed at the 5th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on October 22nd-24th 2015 in Varese, Italy.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  childhood lymphoma; lymphoma; non-Hodgkin lymphoma

Mesh：

Year:  2016        PMID： 27009921      PMCID： PMC4862896          DOI： 10.1111/bjh.14009

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  63 in total

1.  Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma.

Authors:  K Pulford; B Falini; A H Banham; D Codrington; H Roberton; C Hatton; D Y Mason
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

2.  Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.

Authors:  Gesche Tallen; Richard Ratei; Georg Mann; Gertjan Kaspers; Felix Niggli; Alexandr Karachunsky; Wolfram Ebell; Gabriele Escherich; Martin Schrappe; Thomas Klingebiel; Ruediger Fengler; Günter Henze; Arend von Stackelberg
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

3.  Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial.

Authors:  Ilske Oschlies; Wolfram Klapper; Martin Zimmermann; Matthias Krams; Hans-Heinrich Wacker; Birgit Burkhardt; Lana Harder; Reiner Siebert; Alfred Reiter; Reza Parwaresch
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

4.  Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma.

Authors:  Celine Callens; Frederic Baleydier; Etienne Lengline; Raouf Ben Abdelali; Arnaud Petit; Patrick Villarese; Agata Cieslak; Veronique Minard-Colin; Anne Rullier; Anne Moreau; André Baruchel; Claudine Schmitt; Vahid Asnafi; Yves Bertrand; Elizabeth Macintyre
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

5.  ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.

Authors:  Lorena Passoni; Antonio Scardino; Carla Bertazzoli; Barbara Gallo; Addolorata M L Coluccia; François A Lemonnier; Konstadinos Kosmatopoulos; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

Review 6.  Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL.

Authors:  Giovanni Cazzaniga; Elisabetta d'Aniello; Lilia Corral; Andrea Biondi
Journal:  Best Pract Res Clin Haematol       Date:  2002-12       Impact factor: 3.020

7.  Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.

Authors:  Willi Woessmann; Christina Peters; Meike Lenhard; Birgit Burkhardt; Karl-Walter Sykora; Dagmar Dilloo; Bernhard Kremens; Peter Lang; Monika Führer; Thomas Kühne; Reza Parwaresch; Wolfram Ebell; Alfred Reiter
Journal:  Br J Haematol       Date:  2006-04       Impact factor: 6.998

8.  Clinical and pathological features of Burkitt lymphoma showing expression of BCL2--an analysis including gene expression in formalin-fixed paraffin-embedded tissue.

Authors:  Neus Masqué-Soler; Monika Szczepanowski; Christian W Kohler; Sietse M Aukema; Inga Nagel; Julia Richter; Reiner Siebert; Rainer Spang; Birgit Burkhardt; Wolfram Klapper
Journal:  Br J Haematol       Date:  2015-07-27       Impact factor: 6.998

9.  Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.

Authors:  S Goldman; L Smith; J R Anderson; S Perkins; L Harrison; M B Geyer; T G Gross; H Weinstein; S Bergeron; B Shiramizu; W Sanger; M Barth; J Zhi; M S Cairo
Journal:  Leukemia       Date:  2012-09-03       Impact factor: 11.528

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307
View more
  5 in total

1.  IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.

Authors:  Nina Prokoph; Nicola A Probst; Liam C Lee; Jack M Monahan; Jamie D Matthews; Huan-Chang Liang; Klaas Bahnsen; Ivonne A Montes-Mojarro; Elif Karaca-Atabay; Geeta G Sharma; Vikas Malik; Hugo Larose; Sorcha D Forde; Stephen P Ducray; Cosimo Lobello; Qi Wang; Shi-Lu Luan; Šárka Pospíšilová; Carlo Gambacorti-Passerini; G A Amos Burke; Shahid Pervez; Andishe Attarbaschi; Andrea Janíková; Hélène Pacquement; Judith Landman-Parker; Anne Lambilliotte; Gudrun Schleiermacher; Wolfram Klapper; Ralf Jauch; Wilhelm Woessmann; Gilles Vassal; Lukas Kenner; Olaf Merkel; Luca Mologni; Roberto Chiarle; Laurence Brugières; Birgit Geoerger; Isaia Barbieri; Suzanne D Turner
Journal:  Blood       Date:  2020-10-01       Impact factor: 22.113

Review 2.  Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives.

Authors:  Mitchell S Cairo; Auke Beishuizen
Journal:  Br J Haematol       Date:  2019-02-06       Impact factor: 6.998

Review 3.  Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.

Authors:  Nina Prokoph; Hugo Larose; Megan S Lim; G A Amos Burke; Suzanne D Turner
Journal:  Cancers (Basel)       Date:  2018-03-30       Impact factor: 6.639

Review 4.  The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients.

Authors:  Justyna Derebas; Kinga Panuciak; Mikołaj Margas; Joanna Zawitkowska; Monika Lejman
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

5.  Lymphoblastic lymphoma in two young siblings (coincidence or genetics?): two case reports.

Authors:  Naya Talal Hassan; Ebrahim Makhoul; Jafar Sallameh; Abdulmunem Ghanem; Samer Rajab; Waseem Ali; Zuheir Alshehabi
Journal:  J Med Case Rep       Date:  2021-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.